Literature DB >> 34858053

miR-21-5p is a Biomarker for Predicting Prognosis of Lung Adenocarcinoma by Regulating PIK3R1 Expression.

Jianting Du1,2, Jiekun Qian1,2, Bin Zheng1,2, Guobing Xu1,2, Hao Chen1,2, Chun Chen1,2.   

Abstract

BACKGROUND: Lung cancer (LUCA) is one of the most prevalent human malignancies, and the leading cause of cancer-related deaths worldwide. Previous reports have shown that miR-21-5p plays a vital role in development of various tumors. Here, we explored the relationship between miR-21-5p/PIK3R1 axis and prognosis of patients with lung adenocarcinoma (LUAD).
METHODS: MiRNAseq data, deposited in The Cancer Genome Atlas (TCGA) database, was downloaded and used to determine patterns of miR-21-5p expression in both LUAD and normal lung tissues. Statistical analyses and data visualization were performed using dbDEMC v3.0 platform, starBase v3.0 database and packages implemented in R software. Next, we employed TargetScan Human, miRDB and DIANA Tools databases to predict miR-21-5p target genes, then analyzed their expression patterns as well as prognostic value in LUAD.
FINDINGS: Most human cancers overexpressed miR-21-5p. Specifically, miR-21-5p was significantly upregulated in LUAD tissues relative to normal lung tissues (P < 0.001), and this high expression was significantly correlated with poor patient prognosis (hazard ratio [HR]=1.45, P = 0.014). PIK3R1 was predicted as a miR-21-5p target gene, and both were negatively correlated (r=-0.218, P < 0.01). Notably, PIK3R1 was significantly downregulated in LUAD, relative to normal lung tissues (P < 0.01), with its overexpression significantly associated with poor prognosis of LUAD patients (HR = 0.62, P = 0.0014).
CONCLUSION: miR-21-5p is a potential prognostic biomarker for LUAD patients. Moreover, it might be playing a role in LUAD progression by regulating PIK3R1 expression.
© 2021 Du et al.

Entities:  

Keywords:  PIK3R1; lung adenocarcinoma; miR-21-5p; survival

Year:  2021        PMID: 34858053      PMCID: PMC8630376          DOI: 10.2147/IJGM.S337149

Source DB:  PubMed          Journal:  Int J Gen Med        ISSN: 1178-7074


Introduction

Lung cancer (LUCA) is one of the most frequently occurring human malignant cancers, and a leading cause of cancer-related deaths worldwide.1 Histologically, LUCA is categorized into two major types, namely small cell lung cancer or non-small cell lung cancer (NSCLC). The latter is the most common histological type, accounting for approximately 85% of all lung carcinoma cases.2 NSCLC is further classified into three specific pathological subtypes, namely LUAD, lung squamous cell carcinoma and large-cell lung carcinoma, of which LUAD accounts for about 40% of all LUCA cases.3–6 Despite significant progresses in development of diagnostic and therapeutic techniques, prognosis of LUAD patients remains poor due to its unapparent symptoms and signs.7,8 Therefore, elucidating the molecular mechanisms underlying LUAD progression is imperative to development of more effective prognostic and treatment therapies for this group of patients. MicroRNAs (miRNAs), a type of non-coding small RNA molecules encoded by endogenous genes with a length of approximately 19 to 22 nucleotides, have been shown to inhibit gene translation and promote post-transcriptional mRNA degradation by binding to the 3ʹ-untranslated region (UTR) of target mRNAs.9–11 Accumulating evidences have suggested that many miRNAs play a vital role, and serve as oncogenic factors or tumor suppressors, in initiation and progression of cancers.12 For example, miR-21-5p was identified as a distinct oncogenic factor, owing to its over-expression in numerous human cancers, such as prostate cancer, breast cancer (BRCA) and gastric cancer.13–15 Recent reports have demonstrated that miR-21-5p is up-regulated and exerted oncogenic activity in NSCLC.16–18 Furthermore, it has been hypothesized that miR-21-5p may be regulating numerous target genes, thereby causing the unclear biological mechanisms of LUAD. However, the underlying mechanism of this phenomenon remains unclear, necessitating further explorations. In the present study, we carried used bioinformatics analysis to analyze the correlation between differential expression of miR-21-5p with prognosis of LUAD patients. Next, we predicted miR-21-5p’s target genes and found PIK3R1 to be a key target. Furthermore, we explored the relationship between levels of expression and prognostic value of PIK3R1 in LUAD, relative to adjacent normal lung tissues.

Materials and Methods

Analysis of Differential miR-21-5p Expression in Various Human Cancer

Analysis of differential miR-21-5p expression in various human cancer types was performed using the ggplot2 bioconductor package (version 3.3.3) implemented in R statistical software (version 3.6.3) and dbDEMC v3.0 web platform ().

Determination of Differential miR-21-5p Expression Between LUAD and Normal Tissues

Differential expression of miR-21-5p between LUAD and normal lung tissues was conducted using a MiRNAseq dataset deposited in the TCGA database (). The data were converted to log2(RPM+1) values and analyzed statistically using the Mann–Whitney U-test. Statistical analysis and data visualization were performed using the starBase v3.0 platform (starbase.sysu.edu.cn/index.php) and the ggplot2 package in R statistical software, respectively.

Correlation Between miR-21-5p Expression and LUAD Prognosis

To investigate the potential relationship between miR-21-5p expression and prognosis of LUAD patients, we employed the starBase v3.0 database and R software. Statistical analyses were conducted the survival package (version 3.2–10) in R and visualization were performed using the survminer package (version 0.4.9) in R. Overall survival (OS) was chosen as the main prognostic parameter. Next, we stratified the patients into high or low expression groups, based on the median value of their levels of miR-21-5p expression, then applied a Cox regression model for comparisons.

Prediction of Target miR-21-5p Genes in LUAD

Target genes of miR-21-5p in LUAD were predicted using TargetScan Human (), miRDB () and DIANA Tools (). To accurately identify and narrow down the range of predicted target genes, data from TargetScan Human, miRDB and DIANA Tools databases were combined, and a Venn diagram constructed using Venny 2.1 online tool () to visualize the intersection among the three datasets. Several targets, including CREBRF, HGF, LIFR, PIK3R1 and XKR6, were identified in LUAD tissues, and their relationship with miR-21-5p visualized using scatter plots generated using starBase v3.0 project. This allowed selection of target genes with the strongest correlation. Furthermore, we investigated the link between target gene expression levels and survival rates in LUAD.

Analysis of Differential PIK3R1 Expression Between LUAD and Normal Tissues

Differential PIK3R1 expression was analyzed in 526 LUAD cases alongside 59 normal samples using the starBase v3.0 project. Data were visualized using plots generated using the GEPIA web platform ().

Correlation Between Levels of PIK3R1 Expression and Prognosis of LUAD Patients

The relationship between levels of PIK3R1 expression and OS rates of LUAD patients was analyzed using Kaplan–Meier (K-M) survival curves, generated using the GEPIA platform and the survminer and survival packages implemented in R software.

Results

MiR-21-5p is Upregulated in LUAD Relative to Normal Lung Tissues

miR-21-5p was significantly up-regulated in most of human malignancies (P < 0.001), including BRCA, colorectal cancer, and LUCA, among others (Figure 1A and B). Interestingly, miR-21-5p has been confirmed as oncogenes or tumor suppressors in all these tumors, where it plays a regulatory role during initiation and progression of tumors. Analysis of differential expression between LUAD and normal lung tissues revealed that miR-21-5p was significantly upregulated in tumor, relative to adjacent normal tissues (P < 0.001) (Figure 2A and B).
Figure 1

Profiles of differential miR-21-5p expression in cancer and normal tissues using a TCGA dataset. (A) A heatmap showing levels of miR-21-5p expression in pan-cancer; (B) Boxplots showing miR-21-5p expression in pan-cancer.

Figure 2

(A) Boxplots showing differential miR-21-5p expression between LUAD and normal tissues using starBase v3.0 project; (B) Boxplots of miR-21-5p differential expression between LUAD and normal tissues based on R software.

Profiles of differential miR-21-5p expression in cancer and normal tissues using a TCGA dataset. (A) A heatmap showing levels of miR-21-5p expression in pan-cancer; (B) Boxplots showing miR-21-5p expression in pan-cancer. (A) Boxplots showing differential miR-21-5p expression between LUAD and normal tissues using starBase v3.0 project; (B) Boxplots of miR-21-5p differential expression between LUAD and normal tissues based on R software.

miR-21-5p Expression is Correlated with Prognosis of LUAD Patients

The potential association between levels of miR-21-5p expression and OS rates of 503 LUAD patients was investigated using K-M survival curves (Figure 3A and B). miR-21-5p was significantly upregulated and downregulated in 251 (49.9%) and 252 (50.1%) cases, respectively. Notably, high miR-21-5p expression was significantly correlated with poor prognosis of LUAD patients (HR = 1.45, P = 0.014), relative to the low miR-21-5p expression group (Figure 3A). Samples from the 512 patients were stratified into high and low expression groups, based on the median value of miR-21-5p expression, with 259 (50.6%) and 253 (49.4%) Cases, respectively (Figure 3B). As expected, we found statistically significant differences in survival rates in patients between both groups, with low miR-21-5p expression significantly correlated with better prognosis (HR = 1.42, P = 0.021, Figure 3B).
Figure 3

K-M curves showing overall survival of LUAD patients in the high and low miR-21-5p expression group. (A) Survival curves plotted using the starBase v3.0 database; (B) survival curves plotted by R software.

K-M curves showing overall survival of LUAD patients in the high and low miR-21-5p expression group. (A) Survival curves plotted using the starBase v3.0 database; (B) survival curves plotted by R software.

Predicted Target Genes for miR-21-5p in LUAD

To identify miR-21-5p target genes in LUAD tissues, we extracted hundreds of potential candidates using three different and independent miRNA target prediction platforms, namely TargetScan Human, DIANA Tools and miRDB. A Venn diagram combining datasets from the three platforms revealed 142 overlapping target genes (Figure 4A). A comprehensive analysis of the intersecting target genes consequently revealed five targets, namely CREBRF, HGF, LIFR, PIK3R1 and XKR6. Further analysis revealed that the five targets were negatively correlated with miR-21-5p (Figure 4B–F). Among them, PIK3R1 had the strongest correlation to miR-21-5p, as evidenced by a correlation coefficient of −0.218 (P < 0.05) (Figure 4E). In addition, analysis of miRNA-circRNA interactions using Ago CLIP-seq data in ENCORI platform () revealed that the miR-21-5p sequence was complementary to the 3ʹUTR end of PIK3R1 mRNA (Figure 4G).
Figure 4

(A) A Venn diagram depicting the intersection among genes across TargetScan Human, miRDB and DIANA Tools databases; (B–F) correlation between miR-21-5p with CREBRF, HGF, LIFR, PIK3R1, and XKR6; (G) binding sites on PIK3R1 and miR-21-5p.

(A) A Venn diagram depicting the intersection among genes across TargetScan Human, miRDB and DIANA Tools databases; (B–F) correlation between miR-21-5p with CREBRF, HGF, LIFR, PIK3R1, and XKR6; (G) binding sites on PIK3R1 and miR-21-5p.

PIK3R1 is Differentially Expressed in LUAD Relative to Normal Lung Tissues

We generated box-and-whisker plots using GEPIA web platform and starBase v3.0 project to depict differential PIK3R1 expression in LUAD relative to normal lung tissues (Figure 5A and B). Notably, PIK3R1 was significantly downregulated in LUAD than normal lung tissues (P < 0.01), while the numbers of tumors and normal tissues were 483 and 347, respectively. We performed the same analyses using another database and obtained similar results (Figure 5B).
Figure 5

Profile of differential PIK3R1 expression between LUAD and normal lung tissues. (A) Boxplots showing differential PIK3R1 expression between LUAD and normal tissues based on the GEPIA platform; *Means P < 0.01; (B) Boxplots generated based on the starBase v3.0 project.

Profile of differential PIK3R1 expression between LUAD and normal lung tissues. (A) Boxplots showing differential PIK3R1 expression between LUAD and normal tissues based on the GEPIA platform; *Means P < 0.01; (B) Boxplots generated based on the starBase v3.0 project.

Correlation Between PIK3R1 Expression and Prognosis of LUAD Patients

Survival curves revealed that differential PIK3R1 expression had a significant effect on OS rates of LUAD patients (Figure 6A and B). Specifically, high PIK3R1 expression was significantly correlated with high OS rates, while the opposite was true for low expression (HR = 0.59, P = 0.00053), indicating that the high PIK3R1 expression contributes to OS of LUAD patients. Similarly, the results obtained from Figure 6B were consistent with mentioned above information (HR = 0.64, P = 0.003).
Figure 6

Overall survival curves of LUAD patients in the high and low PIK3R1 expression groups. (A) Survival curves plotted by GEPIA platform; (B) survival curves plotted by R software.

Overall survival curves of LUAD patients in the high and low PIK3R1 expression groups. (A) Survival curves plotted by GEPIA platform; (B) survival curves plotted by R software.

Discussion

Until the present time, the incidence and mortality of LUCA dominate a leading position in all human cancers around the world.1,19 Accumulating evidences have demonstrated that many miRNAs play a crucial part in initiation and progression of LUCA. Functionally, some miRNAs have been shown to promote tumorigenesis and progression by repressing expression of tumor-suppressor genes. In fact, some of these miRNAs are considered biomarkers for diagnosis, prognosis and treatment of the disease owing to their significant differential expression in most malignant cancer, relative to adjacent normal tissues. Numerous studies have shown that miR-21-5p, a vital member of miRNA families that is located on human chromosome 17q23.1, is differentially expressed between malignant tumor and adjacent normal tissues. Therefore, miR-21-5p has strongly been associated with proliferation, migration, invasion and apoptosis of tumor cells. For example, Tao et al16 reported that silencing miR-21-5p repressed progression of paclitaxel resistance in BRCA via targeting PDCD4, indicating that it may serve as a therapeutic target in drug-resistant BRCA. In addition, Liu et al20 demonstrated that overexpressing miR-21-5p in gastric cancer cells promoted glycolysis and progression of the disease by downregulating levels of PDHA1 expression. Furthermore, miR-21-5p overexpression in LUAD was associated with disease occurrence and progression through regulation of target genes.21 To date, however, the underlying molecular function of miR-21-5p in LUAD remains unclear. In the present study, we analyzed patterns of miR-21-5p expression in pan-cancer, by comparing expression levels between cancerous and normal tissues and found that it was significantly upregulated in most human malignancies, and more pronounced in LUAD. Our results further indicated that miR-21-5p expression was significantly correlated with and prognosis of LUAD patients, with its high expression associated with poor survival rates of patients. Furthermore, we predicted downstream targets of miR-21-5p across three different programs and analyzed the resulting intersection. Results revealed five candidate target genes, namely CREBRF, HGF, LIFR, PIK3R1 and XKR6, which were all negatively correlated with miR-21-5p expression. Among them, PIK3R1, a regulatory subunit of the phosphoinositide 3-kinase (PI3K) that participates in biological processes in numerous human malignancies,22 was the most relevant target gene. Nonetheless, the molecular function and mechanism of PIK3R1 in LUAD has not been fully elucidated. Further analysis revealed that PIK3R1 is downregulated in LUAD patients with this low expression associated with poor OS of patients relative to those in the high expression group.

Conclusion

Taken together, our results suggest that miR-21-5p might lower OS rates of LUAD patients by down-regulating PIK3R1 expression. However, this molecular mechanism needs to be validated using laboratory experiments to ascertain. We next sought to explore the potential biological mechanism of miR-21-5p/PIK3R1 axis in the initiation and development of LUAD.
  22 in total

1.  MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4.

Authors:  L Tao; Y Q Wu; S P Zhang
Journal:  Neoplasma       Date:  2019-06-03       Impact factor: 2.575

2.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

3.  Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer.

Authors:  Daniel T Merrick; John Kittelson; Ralph Winterhalder; Georgia Kotantoulas; Steen Ingeberg; Robert L Keith; Timothy C Kennedy; York E Miller; Wilbur A Franklin; Fred R Hirsch
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

4.  WWC3 regulates the Wnt and Hippo pathways via Dishevelled proteins and large tumour suppressor 1, to suppress lung cancer invasion and metastasis.

Authors:  Qiang Han; Xuyong Lin; Xiupeng Zhang; Guiyang Jiang; Yong Zhang; Yuan Miao; Xuezhu Rong; Xiaoying Zheng; Yong Han; Xu Han; Jingjing Wu; Joachim Kremerskothen; Enhua Wang
Journal:  J Pathol       Date:  2017-06-29       Impact factor: 7.996

5.  Clinical Significance of let-7a-5p and miR-21-5p in Patients with Breast Cancer.

Authors:  Changguo Chen; Xinping Liu; Changwei Chen; Qiuyuan Chen; Youyou Dong; Bingbing Hou
Journal:  Ann Clin Lab Sci       Date:  2019-05       Impact factor: 1.256

6.  The association between miR-34 dysregulation and distant metastases formation in lung adenocarcinoma.

Authors:  Iben Daugaard; Alice Knudsen; Tina E Kjeldsen; Henrik Hager; Lise Lotte Hansen
Journal:  Exp Mol Pathol       Date:  2017-05-13       Impact factor: 3.362

7.  Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients.

Authors:  Subramanian Kumar; Ranganathan Keerthana; Annamalai Pazhanimuthu; Pachiappan Perumal
Journal:  Indian J Biochem Biophys       Date:  2013-06       Impact factor: 1.918

8.  Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection.

Authors:  Bo-sheng Li; Yong-liang Zhao; Gang Guo; Wei Li; En-dong Zhu; Xiao Luo; Xu-hu Mao; Quan-ming Zou; Pei-wu Yu; Qian-fei Zuo; Na Li; Bin Tang; Kai-yun Liu; Bin Xiao
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

9.  Expression of microRNA‑26b and identification of its target gene EphA2 in pituitary tissues in Yanbian cattle.

Authors:  Bao Yuan; Wang-Yang Yu; Li-Sheng Dai; Yan Gao; Yu Ding; Xian-Feng Yu; Jian Chen; Jia-Bao Zhang
Journal:  Mol Med Rep       Date:  2015-08-06       Impact factor: 2.952

10.  Expression and clinical significance of miR-4516 and miR-21-5p in serum of patients with colorectal cancer.

Authors:  Xi-Han Jin; Sen Lu; Ai-Fen Wang
Journal:  BMC Cancer       Date:  2020-03-23       Impact factor: 4.430

View more
  2 in total

1.  METTL3 m6A-dependently promotes miR-21-5p maturation to accelerate choriocarcinoma progression via the HIF1AN-induced inactivation of the HIF1A/VEGF pathway.

Authors:  Kefan Ye; Lingchuan Li; Bao Wu; Dongjie Wang
Journal:  Genes Genomics       Date:  2022-09-08       Impact factor: 2.164

2.  Calycosin Inhibits the Malignant Behaviors of Lung Adenocarcinoma Cells by Regulating the circ_0001946/miR-21/GPD1L/HIF-1α Signaling Axis.

Authors:  Lixia Zhou; Wenxian Chen; Hang Yang; Jiaqin Liu; Hui Meng
Journal:  Dis Markers       Date:  2022-08-13       Impact factor: 3.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.